In the company's eight-year clinical study, which enrolled 8,302 cancer patients with varying disease type and severity, Escozine was found to have a near 90 percent success rate in improving quality of life, which included everything from decreased pain to increased survival rates. But the company acknowledged that the study was not peer-reviewed, and the results of their trial are not accepted by the American standards of science.
The Good and Great thing about Escozine® is "Not" a Vaccine like those Non FDA Approved by JNJ BNTX NVAX yet...and I'm One of those MultiMillions who will "Not" dare get Injected.
QNTA @ current pps is a Fortune builder for a LongBagholder.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.